AminoChain has recently announced the completion of a $5 million seed funding round, led by the prominent venture capital firm Andreessen Horowitz (a16z). This marks a significant milestone for the company, which has been developing its technology in relative secrecy for the past two years. The core innovation of AminoChain is its Layer 2 blockchain protocol designed specifically for the healthcare sector. This protocol aims to connect enterprise medical institutions and facilitate the development of decentralized healthcare applications that are owned by users. One of the first applications to be launched on the AminoChain platform is a bio-sample marketplace. This marketplace allows researchers to query and license biological samples from a network of biobanks. Patients will have the ability to track how their samples are used, gain insights from the research conducted on their samples, and even receive financial compensation when their samples are sold. AminoChain envisions the creation of a new bioeconomy that operates on-chain, where users can benefit from decentralized applications (D-Apps) in various areas, including clinical recruitment, real-world evidence gathering, and federated learning, among others. For those interested in learning more about AminoChain, its funding round, and potential opportunities to join the founding team, additional resources are available on their website.